n an anticlimactic finish to an embarrassing scandal, the Japanese government has scolded Bayer (BAYRY) for improper promotional activities and, at the same time, ordered the company to bolster its procedures for reporting side effects.

The health ministry issued a verbal guidance after finding Bayer employees “inappropriately” accessed patient data as part of a plan to promote the Xarelto blood thinner. The data was taken from surveys in medical journal papers when Xarelto was launched in 2012 and a former Bayer sales rep claimed he was instructed to gather the data from dozens of patients about dosing and related health matters.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy